Flindr Therapeutics raised €20 million in a Series A funding led by V-Bio Ventures and other new investors to advance its pipeline of small molecule inhibitors for cancer treatment.

Flindr Therapeutics, a precision oncology therapeutics company, has announced a €20 million Series A funding round led by V-Bio Ventures along with other new investors Johnson & Johnson Innovation — JJDC, Inc. (JJDC), QBIC Fund, Flanders Future Tech Fund, and Curie Capital, as well as existing investors Oncode Oncology Bridge Fund, Swanbridge, and Brabantse Ontwikkelings Maatschappij (BOM). The funding will be used to advance its pipeline of small molecule inhibitors for cancer treatment and progress its lead program to IND, develop an exciting second program, and broaden its pipeline using the ImmunoGram Drug Discovery Engine.